Media OutReach
Bora Pharmaceuticals Exits Integration Phase with Sequentially-Improved Gross and Operating Margins
Positioned to Unlock M&A Value through U.S. Manufacturing Amidst Geopolitical Complexities and Specialty Portfolio
HONG KONG SAR – Media OutReach Newswire – 14 May 2025 – Bora Pharmaceuticals (TWSE: 6472) today announced its financial results and operational highlights for first quarter of 2025.
- Fueled by expanded capacity and new dosage forms, Bora’s CDMO business delivered a record high quarter, up 52.4% YoY and 3.0% QoQ.
- As part of Bora’s long-term strategic growth plan, the Company is moving forward with a phased investment of tens of thousands US dollars to unlock the untapped potential of Maple Grove facility. This build-out is designed to enhance capabilities in oral solid dose and sterile manufacturing, strengthening the ability to support customer demand and scale future programs.
- Pharma Sales revenues rose 82.0% YoY based on reported unaudited monthly sales, driven by strong performance from the vigabatrin franchise, which includes three dosage forms. Notably, VIGAFYDE captured over 70% share in the new patient segment.
- Due to the completion of Plymouth area decommissioning, consolidated revenues for 1Q25 was NT$4.48 billion, a NT$350 million reversal from the unaudited monthly disclosures, all of which was attributed to the pharma sales segment.
- Despite margin pressure from partial maintenance shutdowns at the Maryland sterile injectable site in early January and softening demand for generic product dexlansoprazole (DLS), product mix improvement from growing specialty portfolio lifted gross margin from the low of 4Q24 to 42.2% in 1Q25. Tech transfer for 6 Upsher-Smith generic products to cost-competitive sites within Bora network remains on track, with full transfer expected by year-end to support further margin recovery.
- EPS from continuing operations reached NT$26.54, reflecting NT$2.44 billion of net non-operating income from the divestment of Bora Biologics and recognition of losses of Tanvex Biopharm. However, the decommissioning of the Plymouth area negatively impacted EPS by NT$12.99, resulting in a reported EPS of NT$13.55. Share capital increased 0.4% during the quarter from employee stock option exercises and convertible bond conversions.
- DLS competitors began exiting the market in early 2Q25 due to supply chain hiccups, creating new opportunities for Bora to increase share and drive recovery momentum.
- The Group remains optimistic that its first quarter restructuring efforts will increase the long-term value of its recent acquisitions, including unlocking NT$600 million in capital in 2025. CDMO business growth will be further accelerated with strategic U.S.-based capability and capacity.
The closure of Plymouth area was completed ahead of schedule during the quarter and the area has thus been reclassified as discontinued operation in our quarterly financial statements altogether. From an operational standpoint, Bora has discontinued 15 products in the U.S. generics market along with the restructure, with an additional 6 products transferred to more cost-efficient manufacturing sites within the Group. On the financial side, discontinued operation resulted in a negative impact of approximately NT$1.34 billion, including overhead, inventory and equipment write-downs as well as severance-related expenses.
Looking ahead, Bora will advance its focus on high-value and complex dosage forms supported by over NT$5.0 billion cash on hand. At Maple Grove, 4 global pharmaceutical clients are currently in advanced discussions regarding CAPEX investments which we view as a strong validation of the site’s value and strategic fit. While the timeline for full deployment spans several years, we are approaching this expansion with operational discipline and commercial alignment to ensure its success over time.
On pharma sales side, Bora weathered softness in DLS demand in the first quarter but quickly gained market share as a competitor exited in early second quarter. Generic business rebounded in April, supported by strong sales from new 2024 launches including Potassium Chloride ER Tablets (KCL), and anti-angina drugs Diltiazem (DTC and DTS). This recovery underscores Bora’s agility and the resilience of the dual-engine strategy. Furthermore, we have successfully consolidated distribution network for specialty drugs. Bora expects its pediatric spasm product, VIGAFYDE (the 505(b)(2) oral solution), to extend its success in the new patient market into the switch segment in the very near future, supporting future margin and operational leverage expansion.
We continue executing on our goals to scale up, achieve more and integrate smarter, ensuring that both internal and external clients benefit from cost-efficient, regionally aligned manufacturing. By extending the strength of our dual-engine model, we believe Bora shall continue to create above-average total shareholder return.”
Global CDMO Operations
Global CDMO Operations (excluding internal orders) delivered record-high revenues of NT$1.90 billion in the first quarter, up 52.4% YoY and representing approximately 39% of total revenue. Including internal orders, CDMO revenue reached NT$2.89 billion. A total of 600 million doses were developed and manufactured. Revenue contribution from global top 20 pharmaceutical companies remained steady at approximately 30%, demonstrating strong clientele and advantage of scale. Bora CDMO continues to be a trusted partner for biotech and pharmaceutical innovators.
- In 1Q25, the small molecule CDMO pipeline added US$123 million in potential orders and US$78 million in backlog, both marking historic highs.
- CAPEX progress across sites reached approximately 50%, focused on debottlenecks, efficiency improvement, capacity increase and infrastructure upgrade to align with client and product needs. Flex Pro line at the Maryland sterile injectable facility was completed ahead of schedule and is expected to begin operations in early Q3.
- Maple Grove launched its first CDMO project during the quarter and is currently negotiating with potential clients while evaluating CAPEX plans for differentiated dosage platforms. Overall, North American capacity transformation is progressing as planned.
- Large molecule CDMO operation was launched following the January 20 reverse-acquisition of Bora Biologics by Tanvex Biopharm where Bora owns 30.5% of Tanvex. CDMO operations at the San Diego site are now active, and the ongoing 2,000L expansion has received strong interest from late-stage clients. Bora and Tanvex are actively pursuing U.S.-based commercial-scale manufacturing orders with a comprehensive one-stop service model.
Pharma Sales Operations
Pharma Sales Operations revenue reached NT$2.93 billion, representing 82.0% YoY growth and contributing approximately 61% of total revenue based on unadjusted numbers.
- As the Upsher-Smith team continue to consolidate distributors for specialty drugs, we saw early signs of positive engagement from both market and payer channels at the end of the first quarter. Following the 2024 integration of TWi, Upsher-Smith and Pyros teams, Bora has established a focused pipeline in CNS specialty areas. The company expects to file its first self-developed 505(b)(2) submission for infantile spasms (Stiripentol) with the U.S. FDA by year-end, alongside other pipeline developments.
- Pediatric epilepsy and TSC-related rare diseases represent the first wave of Bora’s pharma sales transformation targets. In addition to reducing over-reliance on generics, high-value rare disease and specialty drugs benefit from strong regulatory and payer support in the specialty pharmacy channel. These markets are less competitive with stable price, and offer targeted access to patient populations, allowing for meaningful long-tail value creation.
Bora will host an English online earnings call at 7:00 a.m. Taiwan time on May 15, 2025, followed by an investor conference hosted by Taishin Securities at the Grand Hyatt Taipei at 2:00 p.m. on May 16, 2025. Both events will cover the company’s Q1’25 financial and business results and outlook.
English Online Earnings Presentation Link: https://www.zucast.com/event/54SiM5il/subscribe/create
The 2025 Annual General Shareholders’ Meeting will be held on May 23 at the Tainan Guantian Industrial Marketing Center.
Bora will participate in the Jefferies Global Healthcare Conference in New York on June 4–5. For 1:1 meetings with management, please contact your Jefferies representative.
Q2 2025: Expected in the 3rd week of August 2025
Q3 2025: Expected in the 3rd week of November 2025
Q4 2025: Expected in the 2nd week of March 2026
Hashtag: #Bora
The issuer is solely responsible for the content of this announcement.
About Bora
Founded in 2007, Bora Pharmaceuticals (“Bora” or “the Company”, 6472.TW) is a leading pharmaceutical services company with a vision and goal of “Contributing to Better Health All Over the World”. Operating under a “Dual Engine” model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients’ quality of life.
By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success “certain,” Bora sets new standards in the pharmaceutical and CDMO industries.
For more, please visit:
https://www.bora-corp.com
https://www.boracorpcdmo.com
Disclaimer:
This document and the accompanying information may contain forward-looking statements. All statements regarding the company’s future business operations, potential events, and prospects (including but not limited to forecasts, targets, estimates, and operational plans) are considered forward-looking statements unless they refer to factual occurrences. Forward-looking statements are subject to various factors and uncertainties that may cause significant differences from actual results, including but not limited to price fluctuations, actual demand, exchange rate variations, market share, competitive conditions, changes in the legal, financial, and regulatory framework, international economic and financial market conditions, political risks, cost estimates, and other risks and variables beyond the company’s control. These forward-looking statements are based on current predictions and assessments, and the company disclaims any responsibility for future updates.
Mengniu’s Chinese Culture Pavilion Debuts at the FIFA World Cup, Showcasing Chinese Culture to the World
On the pitch, a single football captures the attention of billions. Beyond the stadium, civilizations come together through cultural exchange.
The Mengniu Chinese Culture Pavilion marks the first comprehensive international presentation of Beijing Central Axis since its inscription as a UNESCO World Heritage Site and debuts at one of the world’s premier sporting events. Inspired by the architectural aesthetics of traditional Chinese architecture and the spatial order of Beijing Central Axis, the pavilion follows a symmetrical layout centered on a principal axis. At its entrance stands the monumental painting Magnificent Central Axis, offering a panoramic bird’s-eye view of Beijing’s historic Central Axis while conveying, through artistic expression, the Eastern philosophy and cultural values it embodies. As visitors explore the pavilion, football fans from around the world pause to experience its interactive exhibits, immersing themselves in the richness of Chinese traditional culture. Standing outside New York New Jersey Stadium, the pavilion continues to tell vivid, contemporary stories of China to a global audience.
Beyond Football: Mengniu Elevates Cultural Exchange on the World Cup Stage
For Mengniu, building a Chinese Culture Pavilion at this FIFA World Cup reflects a deeper understanding of the powerful connection between sport and cultural exchange. Mengniu believes that the FIFA World Cup is not only the pinnacle of football competition but also a global platform where diverse civilizations meet, connect, and learn from one another. As an Official Sponsor of the 2026 FIFA World Cup from China, Mengniu sees it as both an opportunity and a responsibility to share China’s stories and showcase the richness of Chinese civilization with audiences worldwide. This commitment extends beyond football. During the Paris Summer Olympic Games and the Milan Winter Olympic Games, Mengniu, as a Worldwide Olympic Partner (TOP), continuously hosted its signature “China Night” events, integrating Chinese culture into the narrative of the world’s most prestigious sporting competitions.
Beyond a Pavilion: Mengniu’s Multi-Dimensional Presence at the FIFA World Cup
As an Official Sponsor of the 2026 FIFA World Cup, Mengniu’s presence extends far beyond traditional brand visibility. Its participation represents a comprehensive global strategy that integrates products, brand values, and corporate social responsibility.
On the product front, Mengniu Ice Cream has officially become the Official Ice Cream of the 2026 FIFA World Cup. Mengniu Ice Cream is available at all tournament venues and has simultaneously expanded into 11 major U.S. cities, including Los Angeles and New York. By bringing world-class-quality products to international consumers, Mengniu continues to strengthen the commercial foundation for its global growth.
At the brand level, together with global brand ambassadors Lionel Messi, Kylian Mbappé, and Lamine Yamal, Mengniu brings its corporate spirit, “Born for Greatness,” to life on football’s biggest stage. The company has also partnered with Hisense to launch a series of coordinated Chinese-character pitch-side advertising campaigns during the tournament. Moving beyond individual brand promotion, the two companies present a united expression of Chinese brands, confidently demonstrating the growing global influence of Chinese enterprises.
In terms of corporate social responsibility, Mengniu not only brings Chinese culture to the international stage but also demonstrates the commitment of a responsible Chinese enterprise through meaningful public initiatives. At the opening match of this year’s FIFA World Cup, six teenage footballers from Inner Mongolia were selected by Mengniu to escort the FIFA flag onto the field, creating an inspiring example of how businesses can promote youth football development while fulfilling their social responsibilities.
From a glass of milk on store shelves to a cultural journey within the pavilion, Mengniu’s World Cup presence reflects the remarkable evolution of Chinese enterprises on the global stage. Looking ahead, Mengniu will continue to leverage the world’s premier sporting events to advance health, boost brand power, strengthen global presence, and fulfill social responsibilities, contributing the strength of China’s dairy industry to sharing China’s stories and showcasing the enduring appeal of Chinese civilization with the world.
Hashtag: #Mengniu
The issuer is solely responsible for the content of this announcement.
Media OutReach
House of Origin Elevates the Cantonese Culinary Canon with Pristine Expressions for Summer
Michelin-starred culinary director Chef Xu Jingye alongside Resident Chef Tim Lam accentuate the essence of Cantonese cuisine while presenting his signature philosophy of “Refined Homeliness”
MACAU SAR – Media OutReach Newswire – 24 July 2026 – House of Origin, the exclusive private Cantonese dining destination at Galaxy Macau, the world-class luxury integrated resort renowned for its award-winning hospitality and signature “World Class, Asian Heart” service philosophy, continues to captivate discerning gourmands with its exceptional culinary craftsmanship and elegant residential-style setting. Guided by its philosophy of “Refined Homeliness”, House of Origin presents thoughtfully curated dining experiences that reinterpret the rich heritage of Cantonese gastronomy through a contemporary lens.
This season, House of Origin joins forces with China’s iconic baijiu Moutai to present an exclusive “A Journey of Craft and Time – 15-Year Moutai Pairing Dinner presented by House of Origin Masters”, where exquisite aged liquors and masterfully crafted Cantonese delicacies come together in a remarkable celebration of time, terroir and craftsmanship. Complementing this exceptional offering, House of Origin will now cater to patrons with a newly introduced lunch service that unveils an array of new signature dishes, inviting guests to savour its refined Cantonese dining by day for convenience.
When Fine Aged Liquor Meets Vibrant Cantonese Fare
Presented by House of Origin and China’s premium Moutai, the exclusive “A Journey of Craft and Time – 15-Year Moutai Pairing Dinner presented by House of Origin Masters” brings together the artistry of Cantonese cuisine and the timeless character of one of China’s most revered spirits. Available at MOP2,888 per guest for just two evenings on 31 July and 1 August, with only two tables available per night, this intimate experience is designed for discerning guests seeking a truly unique culinary journey.
Curated by two-Michelin-starred Culinary Director Xu and brought to life by Resident Chef Lam, the special menu showcases traditional Cantonese craftsmanship elevated by rare premium ingredients. Each dish has been thoughtfully paired with three remarkable aged Moutai expressions, creating a harmonious dialogue between flavour, aroma and heritage.
The pairing experience features the benchmark 15-Year Aged Moutai, a rare 2011 Feitian Moutai that has matured gracefully in bottle for fifteen years, and an extraordinary 2010 Aged Moutai 15-Year, distinguished by its exceptional depth, richness and complexity. Together, these celebrated spirits offer guests a rare opportunity to appreciate the transformative beauty of time and maturation.
The dinner unfolds as an elegant expression of Cantonese culinary heritage, where tradition and innovation converge in a harmonious journey of flavour. From the nostalgic craftsmanship of the Golden Oyster Roll Wrapped in Caul Fat to the signature House of Origin Abalone infused with Moutai aroma, each course is thoughtfully designed to complement the character and complexity of the accompanying aged Moutai, creating a sensory voyage enriched by time.
The special menu features refined creations such as Wok-fried Conch Slices with Shrimp Paste, Braised Pomelo Pith with Crab Roe and Fish Intestine, Crispy Cinnamon-infused Beef Short Rib, Roasted Goose with Fermented Black Bean and Mint, and Wok-fried Wild Mushroom Medley. Together, the dishes reveal a sophisticated progression of flavours, from rich sauce aromas and deep umami notes to the pure elegance of seasonal ingredients.
Highlights include the Braised Pomelo Pith with Crab Roe and Fish Intestine, a masterful composition balancing freshness, sweetness and savoury complexity with a lingering, refined finish. The Crispy Cinnamon-infused Beef Short Rib captivates with the gentle fragrance of cinnamon and red dates, unfolding layers of warmth and richness. The experience culminates with a comforting Pork and Rice Noodle Roll with Macau’s century-old miso sauce, a tribute to local culinary heritage that provides a memorable and deeply authentic finale.
Complemented by a nourishing herbal soup and delicate petit fours, this exclusive dining experience is more than a pairing of rare aged Moutai and exceptional Cantonese cuisine, offering an unforgettable encounter with the artistry and enduring elegance of Cantonese gastronomy.
The signature dishes featured in “A Journey of Craft and Time – 15-Year Moutai Pairing Dinner” will remain available at House of Origin, offering guests the opportunity to savour the exceptional creations born from the collaboration between Galaxy Macau’s newest Cantonese dining destination and China’s iconic Moutai. Each dish elevates heritage, craftsmanship and refined Cantonese artistry.
Introducing a New Lunch Experience Inspired by the Seasons
Honouring the Cantonese philosophy of seasonal dining, Chef Xu and Chef Lam capture the essence of summer through House of Origin’s newly launched lunch service and seasonal menu. Showcasing an abundance of fresh gourds, vegetables and premium seasonal seafood, the menu also pays tribute to Macau’s culinary heritage through the thoughtful use of ingredients such as shrimp paste by the century-old Kong Hing Loong, reflecting respect for local flavours and traditions.
Designed to meet growing demand for an elevated daytime Cantonese dining experience, the new lunch service extends the warmth and intimacy of House of Origin’s authentic, refined dining concept into the afternoon. Upholding the restaurant’s signature “Refined Homeliness” philosophy, the menu celebrates ingredient purity, seasonality and meticulous craftsmanship.
Leading the “Exquisite Lunch Signature” menu are two newly introduced signature dishes: Crab Meat and Bitter Melon Silky Soup and Black Pepper Geoduck Clam Soup Rice Noodle.
The former combines sweet local bitter melon with fresh crab meat and crab stock to create a silky, refreshing soup with remarkable depth and elegance. The latter showcases a rich ivory-coloured broth simmered for four hours with pork tripe, old hen, pork bones and white peppercorns, accompanied by geoduck clam, wild sole fish fillet and sliced tripe. Finished tableside with the pouring of the fragrant hot broth, the dish delivers both culinary theatre and heart-warming comfort.
The summer menu further celebrates seasonal ingredients such as bitter melon, night-blooming jasmine and winter gourd, alongside premium seafood including young mud crab, fresh abalone, wild grouper and razor clams. Through masterful Cantonese techniques ranging from slow-simmered soups and velvety broths to expertly executed wok-frying, Chef Xu reveals the purest expression of each ingredient.
Among the highlights, Stir-Fried Conch and Partridge with Night-Scented Flower combines the delicate floral fragrance of jasmine blossoms with conch, shrimp, partridge and fresh lily bulbs, finished with crunchy walnuts for added texture and a captivating wok hei. The classic Double-Boiled Winter Melon and Frog with Dried Scallop, inspired by the celebrated Tai Shi Banquet tradition, features tender frog leg and sweet winter melon in a crystal-clear broth simmered for four hours. Equally enticing is Braised Hairy Gourd with Crab Roe Paste, where the natural sweetness of the gourd is elevated by the rich umami of aromatic crab paste.
Meanwhile, the comforting Rice Noodle Soup with Geoduck and Wild Sole embodies the warmth of a traditional family banquet, while the Crab Meat and Duran Bitter Melon Soup, featured on both the lunch and seasonal menus, offers guests a refreshing expression of summer that is both heart-warming and refined.
For the latest updates on Galaxy Macau and House of Origin, please visit: www.galaxymacau.com.
Hashtag: #GalaxyMacau
The issuer is solely responsible for the content of this announcement.
About Galaxy Macau Integrated Resort
Galaxy Macau, The World-class Luxury Integrated Resort delivers the “Most Spectacular Entertainment and Leisure Destination in the World”. Developed at an investment of HK$43 billion, the property covers 1.1 million-square-meter of unique entertainment and leisure attractions that are unlike anything else in Macau. Nine award-winning world-class luxury hotels provide close to 5,000 rooms, suites and villas. They include Banyan Tree Macau, Galaxy Hotel™, Hotel Okura Macau, JW Marriott Hotel Macau, The Ritz-Carlton, Macau, Broadway Hotel, Raffles at Galaxy Macau, Andaz Macau and Capella at Galaxy Macau. Unique to Galaxy Macau, the 75,000-square-meter Grand Resort Deck features the world’s longest Skytop Adventure Rapids at 575-meters, the largest Skytop Wave Pool with waves up to 1.5-meters high and 150-meters pristine white sand beach. Two five-star spas from Banyan Tree Spa Macau and The Ritz-Carlton Spa, Macau help guests relax and rejuvenate.
As the dining destination in Asia, Galaxy Macau offers a wide variety of gastronomic delights, exquisite experiences and ingredients of the finest quality with over 120 dining options from Michelin dining to authentic delicacies; Galaxy Promenade is the hottest shopping destination featuring the latest in fashion and curated experiences in Macau. Spanning over 100,000-square-meter, luxury flagship stores, lifestyle boutiques and our selection of labels are among the more than 200 world-renowned brands for a world-class shopping journey; Galaxy Cinemas, immersive thrills and luxurious comfort go hand in hand at Galaxy Cinemas. All 10 theatres are equipped with the latest audio-visual technology; CHINA ROUGE, one-of-a-kind deluxe lounge that evokes the glitz and glamor of Shanghai’s golden era with entertainment in luxury and style; and Foot Hub presents the traditional art of reflexology to make you feel more relaxed and revitalized. For Authentic Macau Flavours & Vibrant Asian Experiences, Broadway Macau – just a 90-second walk via a bridge from Galaxy Macau, has over 35 Authentic Macau & Asian Flavours at its Broadway Food Street. The 2,500-seat Broadway Theatre plays host to world-class entertainers and a diverse array of cultural events. Meeting, incentive and banquet groups are also well looked after with a portfolio of unique venues in Galaxy Macau and a professional service staff.
Galaxy International Convention Center (GICC) is the latest addition to the Group’s ever-expanding integrated resort precinct and will usher in a new era for the MICE industry in Macau. GICC is a world-class event venue featuring 40,000-square-meter of total flexible MICE, and a 16,000-seat Galaxy Arena – the largest indoor arena in Macau.
For more details, please visit 
www.galaxymacau.com, www.broadwaymacau.com.mo and www.galaxyicc.com.
Media OutReach
Breaking the Bed Bug Control Industry Bottleneck: Nobedbugs-HK Redefines Global Bed Bug Eradication Standards with Proprietary Technology
Targeting Limitations of Conventional Practices: Nobedbugs-HK Engineers Precision-Driven Bed Bug Remediation Solutions
The pest control industry is marked by uneven entry barriers. Most traditional exterminators rely solely on chemical sprays, which only eliminate surface bed bugs. Eggs and nymphs concealed within wall crevices and furniture remain untouched, failing to resolve infestations at their source and leading to frequent recurrences. This superficial treatment model has triggered a steady stream of consumer complaints and dissatisfaction. Compounding the issue, many pest control firms lack the technical expertise and field experience to address tight spaces or cluttered environments, creating treatment blind spots that compromise eradication efficacy and introduce potential safety hazards during operations.
Contrary to the industry’s prevalent profit-driven, perfunctory service model that overpromises underdelivers, Nobedbugs-HK upholds its founding mission of sharing technical expertise to advance the entire sector. Its team regularly conducts technical seminars and exchange programs for property management, hospitality and pest control practitioners across multiple countries and regions. These sessions elaborate on bed bug breeding triggers, transmission pathways, scientific eradication methodologies and routine prevention protocols. The global pest control industry has long grappled with stagnant technology and outdated operational standards. Nobedbugs-HK’s cross-border knowledge exchange initiatives bridge regional technical gaps, steering the industry away from crude, slipshod treatment protocols toward rigorous, science-led remediation. These global outreach efforts have also equipped the brand with an extensive international perspective and cross-jurisdictional service expertise.
Driven by proprietary technological innovation and a global operational vision, Nobedbugs-HK has built its market footprint and sterling professional reputation through consistent, reliable eradication results. Its technological breakthroughs and contributions to the industry have garnered coverage from leading international media outlets. This authoritative global recognition underscores overseas markets’ high regard for Hong Kong’s pest control innovations and validates the city-developed bed bug treatment framework as a benchmark for global adoption.
Self-Developed Thermal Treatment Technology Boosts Bed Bug Remediation Efficiency in High-Rise Buildings
Bed bug control in high-rise structures remains a longstanding technical challenge plaguing pest control professionals worldwide. Conventional extermination methods are only viable for low-rise or open-plan spaces and prove ineffective against the complex structural layouts of high-rises, enabling persistent, recurring bed bug infestations. Addressing this global technical gap, Nobedbugs-HK independently engineered the world’s exclusive thermal treatment system and custom operating procedures tailored specifically for high-rise complexes, delivering a transformative solution to this decades-long industry pain point.
A radical departure from traditional chemical pesticide applications, this proprietary technology leverages physical high-temperature treatment to penetrate the most concealed structural recesses. It eliminates 95% of all bed bug life stages—adults, nymphs and deeply embedded eggs—to sever their reproductive cycle at the root. Complemented by the brand’s exclusive formulations, the treatment creates a long-lasting residual protective barrier that blocks cross-unit bed bug migration from adjacent premises. Unlike chemical-based extermination, high-temperature thermal treatment leaves zero chemical residues, generates no indoor contamination and poses no harm to human occupants, rendering it ideal for residential complexes, hotels, office towers and shopping malls. It resolves the core challenges of bed bug remediation in high-rise buildings with unmatched precision, with no comparable technology or service available globally to date.
Over 10,000 Cases Inform Standardised Service Protocols
Real-world case outcomes serve as the ultimate metric for gauging technological performance. Many industry players offer no efficacy guarantees and provide virtually non-existent after-sales support, leaving clients burdened with recurring infestations and repeated service fees. To date, Nobedbugs-HK has completed over 10,000 bed bug remediation projects solely within Hong Kong, serving residential properties, five-star hotels, corporate office towers and chain enterprises across diverse urban residential and commercial environments. Backed by its proprietary thermal treatment technology and standardised construction workflows, the brand maintains a flawless 100% permanent eradication track record across all cases, effectively suppressing bed bug resurgence with zero treatment failures. Its proven track record of thousands of successful cases has countered widespread industry malpractice, earning widespread acclaim and positive client testimonials across Hong Kong’s online forums and social media platforms.
Beyond its core treatment technology, mainstream commercial pest control products lack targeted efficacy against bed bugs’ unique nesting and reproductive traits, a key driver of recurring infestations. Generic formulations fail to counter the pests’ elusive hiding instincts and rapid breeding cycles, drastically diminishing treatment outcomes. Drawing on data accumulated from over 10,000 field cases, Nobedbugs-HK independently develops and manufactures custom bed bug control formulations. Iteratively refined for deployment across diverse global environments, these safe, non-toxic and long-lasting products are widely recognised by industry practitioners as the gold standard for bed bug mitigation. The brand delivers bespoke, meticulous bed bug eradication solutions tailored for Hong Kong residents, standing in stark contrast to competing service providers that offer minimal after-sales support.
Industry specialists identify two critical barriers to effective bed bug control: the stringent technical requirements for densely populated premises and the complete elimination of infestations at their source—two persistent flaws that have hindered conventional pest control operations for years. Armed with its one-of-a-kind global thermal treatment technology, in-house proprietary formulations, international operational insights and thousands of successful remediation cases, Nobedbugs-HK comprehensively rectifies the shortcomings of traditional extermination models. Beyond providing permanent relief for household and commercial bed bug infestations, the brand has established a new universal benchmark for the global bed bug control industry.
Hashtag: #NobedbugsHK
The issuer is solely responsible for the content of this announcement.
